Unknown

Dataset Information

Agonist that activates the µ-opioid receptor in acidified microenvironments inhibits colitis pain without side effects.


ABSTRACT:

Objective

The effectiveness of µ-opioid receptor (MOPr) agonists for treatment of visceral pain is compromised by constipation, respiratory depression, sedation and addiction. We investigated whether a fentanyl analogue, (±)-N-(3-fluoro-1-phenethylpiperidine-4-yl)-N-phenyl propionamide (NFEPP), which preferentially activates MOPr in acidified diseased tissues, would inhibit pain in a preclinical model of inflammatory bowel disease (IBD) without side effects in healthy tissues.

Design

Antinociceptive actions of NFEPP and fentanyl were compared in control mice and mice with dextran sodium sulfate colitis by measuring visceromotor responses to colorectal distension. Patch clamp and extracellular recordings were used to assess nociceptor activation. Defecation, respiration and l

SUBMITTER: Jimenez-Vargas NN 

PROVIDER: S-EPMC8608554 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature